Vedolizumab

Drug Profile

Vedolizumab

Alternative Names: Entyvio; Kynteles; LDP-02; LPD-02; MLN-0002; MLN-002; MLN-02

Latest Information Update: 21 Apr 2017

Price : $50

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Millennium; Takeda; Takeda Oncology
  • Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Alpha4-beta7 integrin antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Crohn's disease; Ulcerative colitis
  • Phase II Graft-versus-host disease
  • Phase I Malignant melanoma

Most Recent Events

  • 31 Mar 2017 Phase-II clinical trials in Graft-versus-host disease (Treatment-experienced) in USA, France (IV) (NCT02993783) (EudraCT2016-002985-30)
  • 17 Feb 2017 Interim efficacy data from a phase III GEMINI LTS trial in Crohn's disease and Ulcerative colitis released by Takeda
  • 01 Feb 2017 Takeda withdraws phase III trial in Primary sclerosing cholangitis prior to enrolment (NCT03035058)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top